Janssen (Johnson&Johnson)
Janssen is a group of companies which provides virology therapeutics for people living with HIV, hepatitis C and other infectious diseases.
ARVT
- Prezista® (darunavir), coadministered with ritonavir (PREZISTA®/r)
- Edurant (rilpivirine)
- Intelence (etravirine)
- Eviplera (emtricitabine+rilpivirine+tenofovir) – together with Gilead
HepC
- Incivo® (telaprevir)
- Olysio (Sovriad in Russia) (simeprevir)
TB
- Bedaquiline (Sirturo)
Information about the drug products is obtained from public sources or from company representatives and is intended solely for informing community representatives about the options currently available or in development. This information can under no circumstances be intepreted as advertising. The mentioning of any drug products does not mean EECA CAB prioritizes those products or, on the contrary, does not recommend them.
Questions related to access to Janssen’s drugs in EECA countries can be sent to Daria Bychkova, Patient Advocacy Groups Manager: dbychkov@its.jnj.com
EECA CAB’s position regarding Janssen’s policy
An open letter of EECA CAB to Janssen based on the results of the meeting on the 1st of July 2014
